David Last
YOU?
Author Swipe
View article: P11.36.A BARRIER DISRUPTING FIELDS, INDUCING BLOOD-ARACHNOID BARRIER DISRUPTION, ENABLE NON-INVASIVE/EFFICIENT DELIVERY OF ANTIBODIES INTO THE CSF FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE
P11.36.A BARRIER DISRUPTING FIELDS, INDUCING BLOOD-ARACHNOID BARRIER DISRUPTION, ENABLE NON-INVASIVE/EFFICIENT DELIVERY OF ANTIBODIES INTO THE CSF FOR THE TREATMENT OF LEPTOMENINGEAL DISEASE Open
BACKGROUND Leptomeningeal diseases remain exceptionally challenging to treat, primarily due to poor drug penetration across the blood-CSF-barrier, specifically the blood-arachnoid barrier (BAB). We previously demonstrated that barrier disr…
View article: Response assessment of GBM during immunotherapy by delayed contrast treatment response assessment maps
Response assessment of GBM during immunotherapy by delayed contrast treatment response assessment maps Open
Introduction Assessing the treatment response of glioblastoma multiforme during immunotherapy (IT) is an open issue. Treatment response assessment maps (TRAMs) might help distinguish true tumor progression (TTP) and pseudoprogression (PsP)…
View article: BBB opening by low pulsed electric fields, depicted by delayed-contrast MRI, enables efficient delivery of therapeutic doxorubicin doses into mice brains
BBB opening by low pulsed electric fields, depicted by delayed-contrast MRI, enables efficient delivery of therapeutic doxorubicin doses into mice brains Open
Background Pharmacological treatment of CNS diseases is limited due to the presence of the blood-brain barrier (BBB). Recent years showed significant advancement in the field of CNS drug delivery enablers, with technologies such as MR-guid…
View article: Non-Invasive Low Pulsed Electrical Fields for Inducing BBB Disruption in Mice—Feasibility Demonstration
Non-Invasive Low Pulsed Electrical Fields for Inducing BBB Disruption in Mice—Feasibility Demonstration Open
The blood–brain barrier (BBB) is a major hurdle for the treatment of central nervous system disorders, limiting passage of both small and large therapeutic agents from the blood stream into the brain. Thus, means for inducing BBB disruptio…
View article: NIMG-63. THE APPLICATION OF MRI AND TREATMENT RESPONSE ASSESSMENT MAPS (TRAMS) FOR MONITORING TREATMENT EFFECTS DURING/FOLLOWING PROTON BEAM THERAPY – INITIAL EXPERIENCE
NIMG-63. THE APPLICATION OF MRI AND TREATMENT RESPONSE ASSESSMENT MAPS (TRAMS) FOR MONITORING TREATMENT EFFECTS DURING/FOLLOWING PROTON BEAM THERAPY – INITIAL EXPERIENCE Open
BACKGROUND/OBJECTIVES We have previously shown that delayed-contrast-MRI-based TRAMs enable efficient separation between tumor and treatment-effects, validated histologically, reaching 100%/93% sensitivity/PPV to active tumor. Proton beam …
View article: EXTH-14. PULSED ELECTRIC FIELDS FOR THE TREATMENT OF BRAIN TUMORS
EXTH-14. PULSED ELECTRIC FIELDS FOR THE TREATMENT OF BRAIN TUMORS Open
When high pulsed electric fields (PEFs) are applied to the brain electroporation occurs. Depending on the electric fields strength, irreversible electroporation, inducing necrotic cell death or reversible electroporation, inducing BBB disr…
View article: SCIDOT-31. DELAYED CONTRAST MRI FOR HIGH SENSITIVITY DEPICTION OF SUBTLE BBB DISRUPTION IN BRAIN PATHOLOGIES AND AS MEANS FOR MONITORING/DEVELOPING BBB DISRUPTION TECHNOLOGIES
SCIDOT-31. DELAYED CONTRAST MRI FOR HIGH SENSITIVITY DEPICTION OF SUBTLE BBB DISRUPTION IN BRAIN PATHOLOGIES AND AS MEANS FOR MONITORING/DEVELOPING BBB DISRUPTION TECHNOLOGIES Open
Understanding the effects of BBB disrupting technologies on the neurovascular unit is important for safety and for optimal timing of therapeutic agents administration. We studied the effects of two novel BBB disrupting methods employing pu…
View article: P11.22 Radiotherapy effects in GBM Rat model CNS1
P11.22 Radiotherapy effects in GBM Rat model CNS1 Open
BACKGROUND CNS1 is a syngeneic glioma model in Lewis Rats. It is an aggressive infiltrating tumor cell line that mimics important aspects of human GBM such as rapid growth, dispersal along blood vessels and white matter, pseudopallisading …
View article: Transient blood–brain barrier disruption is induced by low pulsed electrical fields in vitro: an analysis of permeability and trans-endothelial electric resistivity
Transient blood–brain barrier disruption is induced by low pulsed electrical fields in vitro: an analysis of permeability and trans-endothelial electric resistivity Open
The blood-brain barrier (BBB) is limiting transcellular and paracellular movement of molecules and cells, controls molecular traffic, and keeps out toxins. However, this protective function is the major hurdle for treating brain diseases s…
View article: A Novel Compound Targeting Protease Receptor 1 Activators for the Treatment of Glioblastoma
A Novel Compound Targeting Protease Receptor 1 Activators for the Treatment of Glioblastoma Open
Data from human biopsies, in-vitro and in-vivo models, strongly supports the role of thrombin, and its protease-activated receptor (PAR1) in the pathology and progression of glioblastoma (GBM), a high-grade glial tumor. Activation of PAR1 …
View article: Radiation-induced vascular malformations in the brain, mimicking tumor in MRI-based treatment response assessment maps (TRAMs)
Radiation-induced vascular malformations in the brain, mimicking tumor in MRI-based treatment response assessment maps (TRAMs) Open
•Of 310 brain tumors patients recruited, histology of 99 lesions was available.•Of those, 5 were histologically confirmed as radiation-induced malformations.•TRAMs cannot differentiate active tumor from vascular malformation.
View article: NIMG-35. TREATMENT RESPONSE ASSESSMENT MAPS (TRAMs) SENSITIVITY TO TUMOR/TREATMENT-EFFECTS AS A FUNCTION OF DATA ACQUISITION PARAMETERS
NIMG-35. TREATMENT RESPONSE ASSESSMENT MAPS (TRAMs) SENSITIVITY TO TUMOR/TREATMENT-EFFECTS AS A FUNCTION OF DATA ACQUISITION PARAMETERS Open
INTRODUCTION: TRAMs calculated from delayed-contrast MRI enable reliable (sensitivity/specificity>70%) differentiation between tumor (blue in the TRAMs) and non-tumoral tissues (red). The TRAMs are calculated by subtracting 3D T1-MRIs acqu…
View article: High‐fat diet protects the blood–brain barrier in an Alzheimer's disease mouse model
High‐fat diet protects the blood–brain barrier in an Alzheimer's disease mouse model Open
Type 2 diabetes (T2D) is associated with increased risk of Alzheimer's disease (AD). There is evidence for impaired blood–brain barrier (BBB) in both diseases, but its role in the interplay between them is not clear. Here, we investigated …
View article: NIMG-52. RADIATION-INDUCED VASCULAR MALFORMATIONS MIMICKING TUMOR IN MRI-BASED TREATMENT RESPONSE ASSESSMENT MAPS (TRAMs)
NIMG-52. RADIATION-INDUCED VASCULAR MALFORMATIONS MIMICKING TUMOR IN MRI-BASED TREATMENT RESPONSE ASSESSMENT MAPS (TRAMs) Open
BACKGROUND: We have recently presented MRI-based TRAMs enabling efficient separation between tumor (contrast clearance >1hour post injection, blue) and treatment-effects (TEs, contrast accumulation, red), validated histologically in 51 res…
View article: NIMG-47. MACHINE LEARNING ALGORITHMS FOR PREDICTING GBM GROWTH PATTERNS USING ADVANCED AND DELAYED-CONTRAST MRI: FEASIBILITY DEMONSTRATION
NIMG-47. MACHINE LEARNING ALGORITHMS FOR PREDICTING GBM GROWTH PATTERNS USING ADVANCED AND DELAYED-CONTRAST MRI: FEASIBILITY DEMONSTRATION Open
We have recently presented delayed-contrast-MRI-based treatment response assessment maps (TRAMs) enabling efficient separation between tumor and treatment-effects, validated histologically in 54 resected patients, reaching 100%/93% sensiti…
View article: P06.14 Early biomarkers from conventional MRI and TRAMs for predicting response to bevacizumab in recurrent high-grade gliomas
P06.14 Early biomarkers from conventional MRI and TRAMs for predicting response to bevacizumab in recurrent high-grade gliomas Open
PURPOSE: We have recently applied a novel technique, in which high resolution treatment response assessment maps (TRAMs) are calculated from MRIs acquired with a delay of >1 hr, enabling efficient separation between tumor (contrast clearan…
View article: Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems
Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems Open
Temozolomide (TMZ) is an alkylating agent that has become the mainstay treatment of the most malignant brain cancer, glioblastoma multiforme (GBM). Unfortunately only a limited number of patients positively respond to it. It has been shown…
View article: Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas
Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas Open
The benefit of contrast-enhanced MR imaging for assessing and predicting the response to bevacizumab was demonstrated. The increased sensitivity of the treatment-response-assessment maps reflects their potential contribution to the managem…
View article: A statistical model describing combined irreversible electroporation and electroporation-induced blood-brain barrier disruption
A statistical model describing combined irreversible electroporation and electroporation-induced blood-brain barrier disruption Open
Background Electroporation-based therapies such as electrochemotherapy (ECT) and irreversible electroporation (IRE) are emerging as promising tools for treatment of tumors. When applied to the brain, electroporation can also induce transie…